{
    "nctId": "NCT00089479",
    "briefTitle": "A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer",
    "officialTitle": "A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2611,
    "primaryOutcomeMeasure": "Disease Free Survival [Number of Events]",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients 18-70 years of age;\n* adenocarcinoma of the breast;\n* previous invasive breast cancer if diagnosed \\>5 years before entering study;\n* no evidence of metastatic disease.\n\nExclusion Criteria:\n\n* history of severe hypersensitivity reaction to Taxotere;\n* previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;\n* treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}